PAREXEL Rebrands Its Technology Subsidiary PAREXEL Informatics; Retains Perceptive Brand For Service Offerings Reflects ongoing commitment to leverage innovation potential between consulting, integrated clinical research and technology-driven services
BOSTON, Feb. 12, 2014 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Perceptive Informatics, the PAREXEL subsidiary that provides the Perceptive MyTrials® eClinical platform and other advanced clinical development technology solutions, has been rebranded PAREXEL Informatics. The Perceptive brand will be used to identify specific PAREXEL Informatics offerings, including the Perceptive MyTrials® eClinical platform, the Perceptive® Partner Program and the Perceptive® Institute.
This alignment further supports the Company's ability to meet growing demand from biopharmaceutical companies for integrated services, as well as underscoring PAREXEL's unique ability to offer a more seamless, fully unified, end-to-end technology and services portfolio to clients around the world.
"As biopharmaceutical companies increasingly seek a combination of solutions from a single service provider, we are more closely integrating our clinical research and technology offerings to meet this need," said Mark A. Goldberg, President and Chief Operating Officer, PAREXEL. "Toward that end, the new PAREXEL Informatics branding communicates our commitment to providing technology-driven solutions that complement our other clinical trial services, without changing our overall go-to-market strategy. At the same time, we'll continue to use the respected Perceptive® brand with certain offerings in recognition of the considerable market equity it has earned over the years."
PAREXEL Informatics is a leading eClinical solutions provider that provides flexible Software-as-a-Service (SaaS) applications and leading technology services to accelerate the drug development process.
"As bringing new drugs to market becomes more complex, particularly in today's global market, companies are relying more on technology to gain a competitive advantage," said Xavier Flinois, President of PAREXEL Informatics. "PAREXEL Informatics helps our clients worldwide simplify and accelerate the drug development process by offering industry-leading technology and services in the context of PAREXEL's deep clinical expertise and global reach."
The new PAREXEL Informatics name is part of the Company's recently announced global corporate branding campaign designed to promote the Company's ability to simplify drug development for clients. The initiative includes the launch of PAREXEL's new brand promise, "Your Journey. Our Mission.™", and a redesigned corporate website that provides an enhanced visitor experience and distinguishes PAREXEL's capabilities in a more client-centric manner.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 76 locations in 50 countries around the world, and has 15,100 employees. For more information about PAREXEL International, visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, Perceptive, Perceptive MyTrials, Perceptive Informatics, and "Your Journey. Our Mission." are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the recent acquisitions of LIQUENT, Inc. and HERON, Inc., or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2013 as filed with the SEC on January 31, 2014, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
Diana Martin, Vice President, Corporate Communications
Tel: +1 781-434-5516
Tel: +1 617-502-4300
SOURCE PAREXEL International Corporation